MICHAEL KELLY: Open Payments
NPI 1740366111 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$916 in 86 payments from 10 companies in 2025. Trend: 2023 $1,236 · 2024 $1,284 · 2025 $916
Food & beverage: $816Education: $100
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 63 | $319 |
| Janssen Biotech, Inc. | 6 | $230 |
| PFIZER INC. | 3 | $78 |
| ABBVIE INC. | 3 | $63 |
| Ferring Pharmaceuticals Inc. | 3 | $57 |
| COLOPLAST CORP | 3 | $56 |
| UROGEN PHARMA, INC. | 2 | $44 |
| Novartis Pharmaceuticals Corporation | 1 | $31 |
| Boston Scientific Corporation | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
Products named: GEMTESA, ERLEADA, ORGOVYX, XTANDI, LUPRON DEPOT, ADSTILADRIN, Luja Coude, RYBREVANT.
Industry payments across OK — which companies pay providers there.
